What is he best known for?
The fields of study he is best known for:
Cell biology, Programmed cell death, Apoptosis, Cancer research and Pharmacology are his primary areas of study.
The concepts of his Cell biology study are interwoven with issues in Caspase, Peptide sequence, Bcl-2 family and Bcl-2-associated X protein.
His Programmed cell death research includes elements of Cell culture, Signal transduction and Immunology.
His study explores the link between Apoptosis and topics such as Molecular biology that cross with problems in Cell type.
His research in Cancer research focuses on subjects like Cell killing, which are connected to Progenitor cell and Large-cell lymphoma.
His Pharmacology research also works with subjects such as
- Leukemia which connect with Navitoclax,
- Cancer which is related to area like MCL1,
- Myeloid Cell Leukemia Sequence 1 Protein that intertwine with fields like Plasma protein binding.
His most cited work include:
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
- Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function (1521 citations)
What are the main themes of his work throughout his whole career to date?
David C.S. Huang mainly focuses on Apoptosis, Cell biology, Cancer research, Programmed cell death and Venetoclax.
His work in Apoptosis addresses issues such as Cell culture, which are connected to fields such as Multiple myeloma.
He interconnects Caspase, Bcl-2 Homologous Antagonist-Killer Protein, Bcl-2 family and Bcl-2-associated X protein in the investigation of issues within Cell biology.
The concepts of his Cancer research study are interwoven with issues in Hematology, Internal medicine, Leukemia, Immunology and MCL1.
His Leukemia study combines topics in areas such as Myeloid, Cancer, Navitoclax and Pharmacology.
David C.S. Huang combines subjects such as Molecular biology, Cell cycle, Mitochondrion and Puma with his study of Programmed cell death.
He most often published in these fields:
- Apoptosis (54.15%)
- Cell biology (45.08%)
- Cancer research (56.99%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (56.99%)
- Venetoclax (32.38%)
- Internal medicine (26.42%)
In recent papers he was focusing on the following fields of study:
David C.S. Huang mostly deals with Cancer research, Venetoclax, Internal medicine, Hematology and Leukemia.
His Cancer research research integrates issues from Cell culture, Apoptosis, Transcription factor, B cell and Multiple myeloma.
David C.S. Huang works in the field of Apoptosis, focusing on Caspase in particular.
His Venetoclax study integrates concerns from other disciplines, such as Mutation, Myeloid leukemia, MCL1 and Lymphoma.
His Internal medicine study combines topics from a wide range of disciplines, such as Neoplasm and Oncology.
His work carried out in the field of Intrinsic apoptosis brings together such families of science as Cell, Bcl-2 Homologous Antagonist-Killer Protein and Cell biology.
Between 2018 and 2021, his most popular works were:
- Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. (129 citations)
- Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. (129 citations)
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. (94 citations)
In his most recent research, the most cited papers focused on:
David C.S. Huang focuses on Venetoclax, Cancer research, Internal medicine, Leukemia and Hematology.
In his research, David C.S. Huang undertakes multidisciplinary study on Cancer research and Neonatal Fc receptor.
His studies in Leukemia integrate themes in fields like Oncology, Myeloid, B cell, Myeloid leukemia and Drug resistance.
His B cell research incorporates elements of Chronic lymphocytic leukemia and Rituximab.
His research in Myeloid leukemia tackles topics such as Myeloid Cell Leukemia Sequence 1 Protein which are related to areas like MCL1.
He has included themes like Apoptosis, Plasma protein binding, Mutant and Binding site in his Mutation study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
